[Federal Register: September 20, 2006 (Volume 71, Number 182)]
[Notices]
[Page 54997-54998]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20se06-65]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004E-0402]
Determination of Regulatory Review Period for Purposes of Patent
Extension; AVASTIN
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for AVASTIN and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Director of Patents
and Trademarks, Department of Commerce, for the extension of a patent
which claims that human biological product.
ADDRESSES: Submit written comments and petitions to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory
Policy (HFD-7), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-594-2041.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Public Law 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Public Law 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human biological products, the
testing phase begins when the exemption to permit the clinical
investigations of the biological product becomes effective and runs
until the approval phase begins. The approval phase starts with the
initial submission of an application to market the human biological
product and continues until FDA grants permission to market the
biological product. Although only a portion of a regulatory review
period may count toward the actual amount of extension that the
Director of Patents and Trademarks may award (for example, half the
testing phase must be subtracted as well as any time that may have
occurred before the patent was issued), FDA's determination of the
length of a regulatory review period for a human biological product
will include all of the testing phase and approval
[[Page 54998]]
phase as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing the human biological product
AVASTIN (bevacizumab). AVASTIN, used in combination with intravenous 5-
fluorouracil-based chemotherapy, is indicated for first-line treatment
of patients with metastatic carcinoma of the colon or rectum.
Subsequent to this approval, the Patent and Trademark Office received a
patent term restoration application for AVASTIN (U.S. Patent No.
6,054,297) from Genentech, Inc., and the Patent and Trademark Office
requested FDA's assistance in determining this patent's eligibility for
patent term restoration. In a letter dated July 8, 2005, FDA advised
the Patent and Trademark Office that this human biological product had
undergone a regulatory review period and that the approval of AVASTIN
represented the first permitted commercial marketing or use of the
product. Shortly thereafter, the Patent and Trademark Office requested
that FDA determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
AVASTIN is 2,551 days. Of this time, 2,401 days occurred during the
testing phase of the regulatory review period, while 150 days occurred
during the approval phase. These periods of time were derived from the
following dates:
1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective: March 5,
1997. The applicant claims February 3, 1997, as the date the
investigational new drug application (IND) became effective. However,
FDA records indicate that the IND effective date was March 5, 1997,
which was 30 days after FDA receipt of the IND.
2. The date the application was initially submitted with respect to
the human biological product under section 351 of the Public Health
Service Act (42 U.S.C. 262): September 30, 2003. The applicant claims
August 29, 2003, as the date the biologics license application (BLA)
for AVASTIN (BLA 125085/0) was initially submitted. The applicant
claims this is the date it submitted the first unit of BLA 125085/0,
which was submitted in several units as part of a rolling application
submission procedure. It is FDA's position that the approval phase
begins when the marketing application is complete. A review of FDA
records reveals that the final module of the BLA 125085/0 was submitted
on September 30, 2003, which is considered to be the complete marketing
application initially submitted date.
3. The date the application was approved: February 26, 2004. FDA
has verified the applicant's claim that BLA 125085/0 was approved on
February 26, 2004.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 307 days of
patent term extension.
Anyone with knowledge that any of the dates as published are
incorrect may submit to the Division of Dockets Management (see
ADDRESSES) written or electronic comments and ask for a redetermination
by November 20, 2006. Furthermore, any interested person may petition
FDA for a determination regarding whether the applicant for extension
acted with due diligence during the regulatory review period by March
19, 2007. To meet its burden, the petition must contain sufficient
facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format
specified in 21 CFR 10.30.
Comments and petitions should be submitted to the Division of
Dockets Management. Three copies of any mailed information are to be
submitted, except that individuals may submit one copy. Comments are to
be identified with the docket number found in brackets in the heading
of this document. Comments and petitions may be seen in the Division of
Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: September 1, 2006.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. E6-15555 Filed 9-19-06; 8:45 am]
BILLING CODE 4160-01-S